Business Context and Reporting Period
Company: iSpecimen Inc. (ISPC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: iSpecimen operates a technology-driven marketplace connecting life science researchers with healthcare providers to procure human biospecimens (biofluids, tissues, cells) and associated data. The company acts as a principal in transactions, procuring specimens on a "just-in-time" basis rather than maintaining speculative inventory.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $1,928,998 | $9,291,115 |
| Cost of Revenue | $1,904,888 | $5,302,712 |
| Gross Profit | $24,110 | $3,988,403 |
| Gross Margin | 1.25% | 42.93% |
| Net Loss | $(10,487,532) | $(12,497,805) |
| Cash and Cash Equivalents | $6,880,835 | $1,878,408 |
| Working Capital | $723,284 | $(2,182,488) |
| Accumulated Deficit | $(82,350,149) | $(71,862,617) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by 79% ($7.36M) primarily due to a 77% drop in specimen volume (from 23,139 to 5,425 specimens) and an 11% decrease in average selling price per specimen.
- Margin Compression: Gross margin collapsed from 42.93% in 2024 to 1.25% in 2025. While cost of revenue decreased 64%, the average cost per specimen increased by 21% ($47), offsetting volume reductions.
- Expense Reduction: Total operating expenses decreased 50% ($11.1M) due to significant workforce reductions (67% reduction in monthly compensation costs) and decreased technology and marketing spend.
- Liquidity Improvement: Cash balances increased by 266% ($5.0M) driven by financing activities, including a private placement and underwritten offering totaling approximately $10.2M in net proceeds.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
The filing includes an explanatory paragraph indicating substantial doubt about the company's ability to continue as a going concern. This is due to recurring losses, an accumulated deficit of $82.35M, and negative cash flows from operations. Management's plan relies on raising additional capital and increasing revenue, but success is not assured.
Material Weakness in Internal Controls
The company identified a material weakness regarding sales tax compliance. Historically, the company failed to collect sales tax on taxable sales. While remediation is underway (engaging tax advisors, implementing software), the company has incurred losses from these obligations and may not recover all prior taxes from customers.
Legal Proceedings
- Focus Technology Solutions: Litigation regarding non-payment for IT services. A settlement was breached, leading to a platform shutdown in early 2025. The company is withholding payments and asserting counterclaims.
- Azenta US, Inc.: Claim for $651,262 regarding sequencing services. Discovery closed; company expects summary judgment motion.
- Krisbio, LLC: Claim for $266,380 regarding a participation agreement.
- EGS (Ellenoff Grossman & Schole): Settled for $200,000 in February 2026 (subsequent event).
Outlook and Strategy
Management is focusing on cost containment, right-sizing the workforce, and shifting to a high-value supplier model. The company is investing in a new cloud-native technology platform (SalesStack) to modernize operations. Revenue trends are described as non-predictive due to the transactional nature of the business and reliance on a few large customers.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $6.88M cash balance against the current burn rate and the timeline for achieving profitability.
- Sales Tax Liability: Confirm the status of the sales tax remediation plan and the potential for additional liabilities or inability to recover taxes from customers.
- Customer Concentration: Assess the risk associated with the top customer, who accounted for approximately 20% of 2025 revenue.
- Legal Exposure: Monitor the resolution of pending litigation (Focus, Azenta, Krisbio) and potential financial impact.
- Internal Controls: Evaluate the progress of remediation for the material weakness in internal controls over financial reporting.
- Stock Listing Status: Note the company's history of Nasdaq non-compliance regarding minimum bid price and the risk of delisting if compliance is not maintained.